NCT04608240 is a clinical trial in Trachea Intubation, sponsored by Fudan University.

Who is sponsoring NCT04608240?

NCT04608240 is sponsored by Fudan University.

What condition does NCT04608240 study?

NCT04608240 studies Trachea Intubation.

Is NCT04608240 still recruiting?

NCT04608240 is currently status unknown. Last updated 2 December 2021.

Last reviewed 2021-12-02 · How we verify

NCT04608240

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surgical Pleth Index: Predicting the Optimal Timing for Tracheal Intubation During General Anesthesia

Status unknown Last updated 2 December 2021

What this trial tests

trial in Trachea Intubation in 102 participants. Status unknown.

Timeline

30 September 2020

Primary endpoint
28 November 2021

30 November 2021

Quick facts

Lead sponsor	Fudan University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	102
Start date	30 September 2020
Primary completion	28 November 2021
Estimated completion	30 November 2021
Sites	1 location across China

Conditions studied

Trachea Intubation — all drugs for Trachea Intubation →

Sponsor

Fudan University

Who can join

Adults 18 to 80, any sex, with Trachea Intubation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgical pleth index (SPI) has been widely investigated in assessing the nociceptive level, and tracheal intubation is a noxious stimulus during the induction of anesthesia. This study aims to evaluate the ability of SPI to predict hemodynamic reactivity after tracheal intubation, and find the target value of SPI to guide the optimal timing for tracheal intubation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04608240 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 2 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04608240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing